{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:10:18Z","timestamp":1733789418124,"version":"3.30.1"},"reference-count":35,"publisher":"Georg Thieme Verlag KG","issue":"12","funder":[{"name":"Research and Development Fund of Peking University People\u02bcs\n                        Hospital","award":["RDL2022-20"],"award-info":[{"award-number":["RDL2022-20"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Denosumab is a completely human monoclonal high-affinity antibody that binds to\n                    the nuclear factor kappa-B ligand (RANKL) and is widely used to treat\n                    osteoporosis. Furthermore, it can potentially lower serum calcium levels by\n                    inhibiting osteoclast activation and preventing bone calcium from being released\n                    into the blood. This review aimed to provide evidence of the efficacy and safety\n                    of denosumab in treating hypercalcemia in primary hyperparathyroidism (PHPT).\n                    PubMed and the Cochrane Library were searched for published studies that\n                    described denosumab for hypercalcemia management in PHPT. Data were extracted by\n                    two independent investigators and analyzed using SPSS 23. The risk of bias was\n                    assessed by NIH Quality Assessment Tool. In total, 161 patients with PHPT from\n                    18 studies were included in this review. The average age was 61 (47\u201372) years\n                    and the highest serum calcium was 3.76 (3.11\u20134.20) mmol\/l. We found that\n                    denosumab can effectively reduce the serum calcium level by a median reduction\n                    of 0.5 mmol\/l within 3 days. Significant reduction was maintained for 14 days.\n                    The serum calcium-lowering effect weakened after one month. In conclusion,\n                    denosumab has a potential clinical value in treating hypercalcemia in patients\n                    with PHPT.<\/jats:p>","DOI":"10.1055\/a-2411-9426","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T23:05:31Z","timestamp":1728687931000},"page":"839-844","source":"Crossref","is-referenced-by-count":0,"title":["Denosumab for Management of Hypercalcemia in Primary\n                    Hyperparathyroidism"],"prefix":"10.1055","volume":"56","author":[{"given":"Yihan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking\n                    University People\u02bcs Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking\n                    University People\u02bcs Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking\n                    University People\u02bcs Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaona","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking\n                    University People\u02bcs Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leili","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking\n                    University People\u02bcs Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking\n                    University People\u02bcs Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyao","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking\n                    University People\u02bcs Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linong","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Peking\n                    University People\u02bcs Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrendo.2017.104","article-title":"Primary hyperparathyroidism","volume":"14","author":"M D Walker","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1681\/ASN.V12suppl_1s3","article-title":"Hypercalcemic crisis","volume":"12","author":"R Ziegler","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamasurg.2016.2310","article-title":"The American association of endocrine surgeons guidelines for definitive\n                    management of primary hyperparathyroidism","volume":"151","author":"S M Wilhelm","year":"2016","journal-title":"JAMA Surg"},{"key":"ref4","first-page":"Cd013035","article-title":"Parathyroidectomy for adults with primary hyperparathyroidism","volume":"3","author":"J M Pappachan","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with\n                    osteoporosis","volume":"361","author":"S R Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the treatment of osteoporosis: 10 years later: a narrative\n                    review","volume":"39","author":"D L Kendler","year":"2022","journal-title":"Adv Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1530\/EJE-21-1044","article-title":"European expert consensus on practical management of specific aspects of\n                    parathyroid disorders in adults and in pregnancy: recommendations of the ESE\n                    educational program of parathyroid disorders","volume":"186","author":"J Bollerslev","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/jgs.15250","article-title":"Protective effect of denosumab on bone in older women with primary\n                    hyperparathyroidism","volume":"66","author":"C Eller-Vainicher","year":"2018","journal-title":"J Am Geriatr Soc"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1530\/EC-20-0380","article-title":"Denosumab for management of severe hypercalcemia in primary\n                    hyperparathyroidism","volume":"9","author":"A Eremkina","year":"2020","journal-title":"Endocr Connect"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s12020-023-03381-z","article-title":"Denosumab for osteoporosis in patients with primary hyperparathyroidism and\n                    mild-to-moderate renal insufficiency","volume":"81","author":"S Gronskaya","year":"2023","journal-title":"Endocrine"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S2213-8587(20)30063-2","article-title":"Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a\n                    randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"J S Leere","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s12020-020-02401-6","article-title":"Effects of denosumab as compared with parathyroidectomy regarding calcium,\n                    renal, and bone involvement in osteoporotic patients with primary\n                    hyperparathyroidism","volume":"69","author":"D Miyaoka","year":"2020","journal-title":"Endocrine"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"757","DOI":"10.29271\/jcpsp.2020.07.757","article-title":"Control of refractory hypercalcemia with denosumab in a case of metastatic\n                    parathyroid carcinoma","volume":"30","author":"M \u00c7alapkulu","year":"2020","journal-title":"J Coll Physicians Surg Pak"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40463-022-00600-x","article-title":"Primary hyperparathyroidism presenting as acute hypercalcemic crisis: a case\n                    report","volume":"52","author":"G Gill","year":"2023","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"ref15","first-page":"150082","article-title":"Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis:\n                    denosumab as rescue therapy","volume":"2015","author":"R Jumpertz von Schwartzenberg","year":"2015","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref16","first-page":"669","article-title":"Denosumab can be used successfully as a bridge to surgery in patients with\n                    severe hypercalcemia due to primary hyperparathyroidism","volume":"65","author":"M S Kuchay","year":"2021","journal-title":"Arch Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"e10324","DOI":"10.1002\/jbm4.10324","article-title":"Severe primary hyperparathyroidism caused by parathyroid carcinoma in a\n                    13-year-old child; novel findings from HRpQCT","volume":"4","author":"N Lenherr-Taube","year":"2020","journal-title":"JBMR Plus"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e233665","DOI":"10.1136\/bcr-2019-233665","article-title":"Pitfalls of using denosumab preoperatively to treat refractory severe\n                    hypercalcaemia","volume":"13","author":"Y Li","year":"2020","journal-title":"BMJ Case Rep"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.2169\/internalmedicine.9261-21","article-title":"Successful control of hypercalcemia with sorafenib, evocalcet, and denosumab\n                    combination therapy for recurrent parathyroid carcinoma","volume":"61","author":"H Makino","year":"2022","journal-title":"Intern Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40792-020-00914-w","article-title":"Parathyroid carcinoma in a 13-year-old girl with a long-term survival","volume":"6","author":"Y Omi","year":"2020","journal-title":"Surg Case Rep"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4103\/ijem.IJEM_678_18","article-title":"Denosumab as a bridge to surgery in a patient with severe hypercalcemia due to\n                    primary hyperparathyroidism in the setting of renal dysfunction","volume":"23","author":"R Rajan","year":"2019","journal-title":"Indian J Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"794988","DOI":"10.3389\/fendo.2021.794988","article-title":"Denosumab for the treatment of hypercalcemia in a patient with parathyroid\n                    carcinoma: a case report","volume":"12","author":"A Roukain","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref23","first-page":"151","article-title":"The use of denosumab in a nonagenarian with primary hyperparathyroidism","volume":"10","author":"T Shalaby","year":"2014","journal-title":"Eur Endocrinol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s42000-021-00343-w","article-title":"Effective long-term management of parathyromatosis-related refractory\n                    hypercalcemia with a combination of denosumab and cinacalcet treatment","volume":"21","author":"T Tzotzas","year":"2022","journal-title":"Hormones (Athens)"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1210\/jc.2013-3031","article-title":"Denosumab for management of parathyroid carcinoma-mediated hypercalcemia","volume":"99","author":"P Vellanki","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3344\/kjp.2017.30.2.86","article-title":"Can denosumab be a substitute, competitor, or complement to\n                    bisphosphonates?","volume":"30","author":"S Y Kim","year":"2017","journal-title":"Korean J Pain"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.amjmed.2014.09.030","article-title":"Hypercalcemic crisis: a clinical review","volume":"128","author":"S Ahmad","year":"2015","journal-title":"Am J Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/adc.76.1.73","article-title":"Biphosphonates","volume":"76","author":"J Allgrove","year":"1997","journal-title":"Arch Dis Child"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"M A Perazella","year":"2008","journal-title":"Kidney Int"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.10-90001-3","article-title":"Preclinical perspectives on bisphosphonate renal safety","volume":"10","author":"J J Body","year":"2005","journal-title":"Oncologist"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11154-021-09694-6","article-title":"The efficacy and safety of cinacalcet in primary hyperparathyroidism: a\n                    systematic review and meta-analysis of randomized controlled trials and cohort\n                    studies","volume":"23","author":"M Chandran","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1507\/endocrj.EJ19-0034","article-title":"Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single\n                    center experience","volume":"66","author":"K Manaka","year":"2019","journal-title":"Endocr J"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1210\/jc.2009-1472","article-title":"Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone\n                    densitometric outcomes in a five-year study","volume":"94","author":"M Peacock","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed\n                    multiple myeloma: an international, double-blind, double-dummy, randomised,\n                    controlled, phase 3 study","volume":"19","author":"N Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1590\/0004-2730000003381","article-title":"Bone disease in primary hyperparathyroidism","volume":"58","author":"F Bandeira","year":"2014","journal-title":"Arq Bras Endocrinol Metabol"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2411-9426.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T23:32:57Z","timestamp":1733787177000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2411-9426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":35,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,9]]},"published-print":{"date-parts":[[2024,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2411-9426","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"type":"print","value":"0018-5043"},{"type":"electronic","value":"1439-4286"}],"subject":[],"published":{"date-parts":[[2024,10,11]]}}}